European regulators won’t recommend weight loss drug containing Topamax ingredient

The European Medicines Agency (EMA) has recommended not to approve a new weight loss drug that contains topiramate, the active drug in Topamax. The EMA expressed concerns about the long-term risks of cardiovascular problems and other side effects associated with the drug, known as Qsymia.

Read more about the side effects caused by drugs containing topiramate…

0 Responses to “European regulators won’t recommend weight loss drug containing Topamax ingredient”



  1. Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s




Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 434 other followers

Contact Us:

Hissey Kientz, LLP

9442 Capital of Texas Hwy N.

Arboretum Plaza One, Suite 400

Austin, Texas 78759

Toll-free: (866) 275-4454

Facsimile: (512) 320-9101

Email: info@hkllp.com

Sponsored By:

Hissey Kientz, LLP (Austin, TX)

Attorney Michael Hissey is responsible for the content of this website.


%d bloggers like this: